Entecavir is a nucleoside analogue used in the treatment of chronic hepatitis B for patients with active viral replication, histological evidence of active disease, or persistent elevations in liver transaminases. It is marketed under the trade name Baraclude (BMS).
- Mechanism
- Curator reviewed
By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity.
- Primary indication
- For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.Curator reviewed · 1 structured indication
- Formula / weight
- C12H15N5O3 · 277.2792 g/mol (avg)
- First approval
- Canada, 2006 · United States, 2005 · European Union, 2016
- Code names
- BMS-200475-01 · ETV · SQ-34676
- Brand names
Resolves to
QDGZDCVAUDNJFG-FXQIFTODSA-NSMILESNC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Entecavir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account